Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
CMOs showed an increasing reluctance to take on debt in 2022
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Moist wound dressing for chronic wound treatment now available in Germany
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Approval to dramatically change CAR-T therapies landscape
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Subscribe To Our Newsletter & Stay Updated